How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts

 
• By Sue Sutter

Drug Review Profile examines how Amgen persuaded US agency that its preferred distinguishable suffix choice for Amjevita, a biosimilar to AbbVie’s Humira, would not be confused with medical abbreviations or existing trademarks.

More from Drug Review Profiles

More from Product Reviews